Pentamidine uptake and resistance in pathogenic protozoa: Past, present and future

Trends in Parasitology

Volumn 19, Issue 5, 2003, Pages 232-239

  Bray, Patrick G ^a   Barrett, Michael P ^b   Ward, Stephen A ^a   De Koning, Harry P ^b  

^a LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; ANTIMALARIAL AGENT; ANTINEOPLASTIC AGENT; DIMINAZENE ACETURATE; ISOMETAMIDIUM; MELARSOPROL; PENTAMIDINE; PROCHLORPERAZINE; PUTRESCINE; SPERMIDINE; TRIFLUOPERAZINE; VERAPAMIL;

AFRICAN TRYPANOSOMIASIS; ANTIBACTERIAL ACTIVITY; ANTIFUNGAL ACTIVITY; ANTIMALARIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; DRUG EFFECT; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG TRANSPORT; DRUG UPTAKE; HUMAN; LEISHMANIA; LEISHMANIA MEXICANA; LEISHMANIASIS; MALARIA; NONHUMAN; PLASMODIUM FALCIPARUM; PNEUMOCYSTIS PNEUMONIA; PROTOZOON; REVIEW; TREATMENT INDICATION; TRYPANOSOMA BRUCEI;

LEISHMANIA MEXICANA; PLASMODIUM FALCIPARUM; PNEUMOCYSTIS CARINII; PROTOZOA; TRYPANOSOMA; TRYPANOSOMA BRUCEI;

EID: 0038742717     PISSN: 14714922     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1471-4922(03)00069-2     Document Type: Review

References (71)

1. Von Janscó N., Von Janscó H. Chemotherapeutische Wirkung und Kohlehydratstoffwechsel: die Heilwirking von Guanidinderivaten auf die Trypanosomeninfektion. Z. Immunitätsforsch. Exper. Ther. 86:1935;1-30.
2. King H., et al. New trypanocidal substances. Lancet. 223:1937;1360-1363.
3. Lourie E.M., Yorke W. Sudies in chemotherapy XXI. The trypanocidal action of certain aromatic diamidines. Ann. Trop. Med. Parasitol. 33:1939;289-304.
4. Lourie E.M. Treatment of sleeping sickness in Sierra Leone. Ann. Trop. Med. Parasitol. 36:1942;113-131.
5. Napier L.E., et al. The treatment of Kala-Azar by diamidino stilbene: analysis of 101 cases. Indian Med. Gaz. 77:1942;71-74.
6. Napier L.E., Sen Gupta P.C. A peculiar neurological sequel to administration of 4:4″-diamidino-diphenyl-ethylene (M&B 744). Indian Med. Gaz. 77:1942;71-74.
7. Van Hoof L., et al. Pentamidine in the prevention and treatment of trypanosomiasis. Trans. R. Soc. Trop. Med. Hyg. 37:1944;271-280.
8. Goa K.L., Camploi-Richards D.M. Pentamidine isethionate: a review of its antiprotozoal activity, pharmacokinetic properties and therapeutic use in Pneumocystis carinii pneumonia. Drugs. 33:1987;242-258.
9. Schoenbach E.B., Greenspan E.M. The pharmacology, mode of action and therapeutic potentialities of stilbamidine, pentamidine, propamidine and other aromatic diamidines - a review. Medicine (Baltimore). 27:1948;327-377.
10. Damper D., Patton C.L. Pentamidine transport and sensitivity in brucei-group trypanosomes. J. Protozool. 23:1976;349-356.
11. Damper D., Patton C.L. Pentamidine transport in Trypanosoma brucei: kinetics and specificity. Biochem. Pharmacol. 25:1976;271-276.
12. Shapiro T.A., Englund P.T. Selective cleavage of kDNA minicircles promoted by antitrypanosomal drugs. Proc. Natl. Acad. Sci. U. S. A. 87:1990;950-954.
13. Carter N.S., et al. Uptake of diamidine drugs by the P2 nucleoside transporter in melarsen-sensitive and -resistant Trypanosoma brucei brucei. J. Biol. Chem. 270:1995;28153-28157.
14. Carter N.S., Fairlamb A.H. Arsenical resistant trypanosomes lack an unusual adenosine transporter. Nature. 361:1993;173-175.
15. Mäser P., et al. A nucleoside transporter from Trypanosoma brucei involved in drug resistance. Science. 285:1999;242-244.
16. Barrett M.P., Fairlamb A.H. The biochemical basis of arsenical-diamidine crossresistance in African trypanosomes. Parasitol. Today. 15:1999;136-140.
17. De Koning H.P., Jarvis S.M. Mol. Pharmacol. Purine transporters in bloodstream forms of T. b. brucei: Substrate recognition motifs and affinity for trypanocidal drugs. 56:1999;1162-1170.
18. De Koning H.P. Uptake of pentamidine in Trypanosoma brucei brucei is mediated by three distinct transporters. Implications for crossresistance with arsenicals. Mol. Pharmacol. 59:2001;586-592.
19. De Koning H.P., Jarvis S.M. Uptake of pentamidine in Trypanosoma brucei brucei is mediated by the P2 adenosine transporter and at least one novel, unrelated transporter. Acta Trop. 80:2001;245-250.
20. Waalkes T.P., DeVita V.T. The determination of pentamidine (4, 4-diamidinophenoxypentane) in plasma, urine, and tissues. J. Lab. Clin. Med. 75:1970;871-878.
21. De Koning H.P., et al. Characterisation of a nucleoside/proton symporter in procyclic Trypanosoma brucei brucei. J. Biol. Chem. 273:1998;9486-9494.
22. De Koning H.P., Diallinas G. Nucleobase transporters (review). Mol. Membr. Biol. 75:2000;75-94.
23. De Koning H.P. Transporters in African trypanosomes: role in drug action and resistance. Int. J. Parasitol. 31:2001;511-521.
24. Fairlamb A.H., et al. Characterisation of melarsen-resistant Trypanosoma brucei brucei with respect to cross-resistance to other drugs and trypanothione metabolism. Mol. Biochem. Parasitol. 53:1992;213-222.
25. Zhang Z.Q., et al. In vivo and in vitro sensitivity of Trypanosoma evansi and T. equiperdum to diminazene, suramin, MelCy, quinapyramine and isometamidium. Acta Trop. 50:1992;101-110.
26. Matovu E., et al. Susceptibility of Ugandan Trypanosoma brucei rhodesiense isolated from man and animal reservoirs to diminazene, isometamidium and melarsoprol. Trop. Med. Int. Health. 2:2001;13-18.
27. Berger B.J., et al. Characterisation of pentamidine-resistant Trypanosoma brucei brucei. Mol. Biochem. Parasitol. 69:1995;289-298.
28. Gastellu-Etchegorry M., et al. Availability and affordability of treatment for human African trypanosomiasis. Trop. Med. Int. Health. 6:2001;957-959.
29. Matovu E., et al. Melarsoprol refractory T. b. gambiense from Omugo, north-western Uganda. Trop. Med. Int. Health. 6:2001;407-411.
30. Brun R., et al. The phenomenon of treatment failures in human African trypanosomiasis. Trop. Med. Int. Health. 6:2001;906-914.
31. Croft S.L., Yardley V. Chemotherapy of leishmaniasis. Curr. Pharm. Des. 8:2000;319-342.
32. Croft S.L. Monitoring drug resistance in leishmaniasis. Trop. Med. Int. Health. 6:2001;899-905.
33. Becker I., et al. The efficacy of pentamidine combined with allopurinol of patients with diffuse cutaneous leishmaniasis. Parasitol. Res. 85:1999;165-170.
34. Sands M., et al. Pentamidine: a review. Rev. Infect. Dis. 7:1985;625-634.
35. Soto-Mancipe J., et al. Successful treatment of Colombian cutaneous leishmaniasis with four injections of pentamidine. Am. J. Trop. Med. Hyg. 50:1994;107-111.
36. Kandpal M., et al. Kinetics and molecular characteristics of arginine transport by Leishmania donovani promastigotes. Mol. Biochem. Parasitol. 71:1995;193-201.
37. Reguera R., et al. Putrescine uptake inhibition by aromatic diamidines in Leishmania infantum promastigotes. Biochem. Pharmacol. 47:1994;1859-1866.
38. Basselin M., et al. Putrescine and spermidine transport in Leishmania. Mol. Biochem. Parasitol. 109:2000;37-46.
39. Basselin M., et al. Resistance to pentamidine in Leishmania mexicana involves exclusion from the mitochondrion. Antimicrob. Agents Chemother. 46:2002;3731-3738.
40. Basselin M., et al. Effects of pentamidine on polyamine level and biosynthesis in wild-type, pentamidine-treated and pentamidine-resistant Leishmania. Exp. Parasitol. 85:1997;274-282.
41. Basselin M., et al. Altered transport properties of pentamidine-resistant Leishmania donovani and L. amazonensis promastigotes. Parasitol. Res. 83:1997;413-418.
42. Basselin M., et al. Modification of kinetoplast DNA minicircle composition in pentamidine-resistant Leishmania. Acta Trop. 70:1998;43-61.
43. Basselin M., Robert-Gero M. Alterations in membrane fluidity, lipid metabolism, mitochondrial activity, and lipophosphoglycan expression in pentamidine-resistant Leishmania. Parasitol. Res. 60:1998;78-83.
44. Giri O.P. Treatment of visceral leishmaniasis unresponsive to pentamidine with amphotericin B. J. Assoc. Physicians India. 42:1994;688-689.
45. Sereno D., et al. Phenotypic characterization of Leishmania mexicana pentamidine-resistant promastigotes. Modulation of the resistance during in-vitro developmental life cycle. C. R. Acad. Sci. III. 320:1997;981-987.
46. Sereno D., Lemesre J.L. In vitro life cycle of pentamidine-resistant amastigotes: stability of the chemoresistant phenotypes is dependent on the level of resistance induced. Antimicrob. Agents Chemother. 41:1997;1898-1903.
47. Croft S.L., Brazil R.P. Effect of pentamidine isethionate on the ultrastructure and morphology of Leishmania mexicana amazonensis in vitro. Ann. Trop. Med. Parasitol. 76:1982;37-43.
48. Hentzer B., Kobayasi T. The ultrastructural changes of Leishmania tropica after treatment with pentamidine. Ann. Trop. Med. Parasitol. 71:1977;157-166.
49. 2+, pentamidine and WR-6026 on mitochondrial membrane potential in situ. Biochem. J. 284:1992;463-467.
50. Ludewig G., Staben C. Characterization of the PNT1 pentamidine resistance gene of Saccharomyces cerevisiae. Antimicrob. Agents Chemother. 38:1994;2850-2856.
51. He S., Fox T.D. Mutations affecting a yeast mitochondrial inner membrane protein Pnt1p, block export of a mitochondrially synthesized fusion protein from the matrix. Mol. Cell. Biol. 19:1999;6598-6607.
52. Moreno S.N. Pentamidine is an uncoupler of oxidative phosphorylation in rat liver mitochondria. Arch. Biochem. Biophys. 326:1996;15-20.
53. Wilkes J.M., et al. Modulation of mitochondrial electrical potential: a candidate mechanism for drug resistance in African trypanosomes. Biochem. J. 326:1997;755-761.
54. Christophers S.R., Fulton J.D. Observations on the course of Plasmodium knowlesi infection in monkeys (Macacus rhesus), with notes on its treatment by (1) atebrin and (2) 1:11 normal undecane diamidine together with a note on the latter on bird malaria. Ann. Trop. Med. Parasitol. 32:1938;257-278.
55. Fulton J.D. The course of Plasmodium relictum infection in canaries and the treatment of bird and monkey malaria with synthetic bases. Ann. Trop. Med. Parasitol. 34:1940;53-66.
56. Sen Gupta P.C. 4:4′-Diamidino-diphenyl ether in the treatment of Indian kala azar. Indian Med. Gaz. 80:1945;495-498.
57. Bell C.A., et al. Structure-activity relationships of analogs of pentamidine against Plasmodium falciparum and Leishmania mexicana amazonensis. Antimicrob. Agents Chemother. 34:1990;1381-1386.
58. Stead A.M.W., et al. Diamidine compounds: Novel antimalarials with two levels of selectivity against Plasmodium falciparum. Mol. Pharmacol. 59:2001;1298-1306.
59. Desai S.A., et al. A voltage-dependent channel involved in nutrient uptake by red blood cells infected with the malaria parasite. Nature. 406:2000;1001-1005.
60. Kirk K. Membrane transport in the malaria-infected erythrocyte. Physiol. Rev. 81:2001;495-537.
61. Bray P.G., et al. Cellular uptake of chloroquine is dependent on binding to ferriprotoporphyrin IX and is independent of NHE activity in Plasmodium falciparum. J. Cell Biol. 145:1999;363-376.
62. Francis S.E., et al. Hemoglobin metabolism in the malaria parasite Plasmodium falciparum. Annu. Rev. Microbiol. 51:1997;97-123.
63. Harding R.D. Late results of treatment of sleeping sickness in Sierra Leone by antrypol, tryparsamide, pentamidine, and propamidine singly and in various combinations. Trans. R. Soc. Trop. Med. Hyg. 39:1945;99-124.
64. Duggan A.J., Hutchinson M.P. The efficacy of certain trypanocidal compounds against Trypanosoma gambiense infection in man. Trans. R. Soc. Trop. Med. Hyg. 44:1951;535-544.
65. Doua F., et al. The efficacy of pentamidine in the treatment of early-late stage Trypanosoma brucei gambiense trypanosomiasis. Am. J. Trop. Med. Hyg. 55:1996;586-588.
66. Legros D., et al. Treatment of human African trypanosomiasis - present situation and needs for research and development. Lancet Infect. Dis. 2:2002;437-440.
67. Van-Hoof A., et al. A field experiment on prophylactic value of pentamidine in sleeping sickness. Trans. R. Soc. Trop. Med. Hyg. 39:1946;327-329.
68. Organisation de Coordination pour la Lutte contre les Endemies en Afrique Centrale (OCEAC) (1968) Rapport final de la deuxieme conference technique.
69. Labusquière R., Dutertre J. La lutte contre les derniers foyers de trypanosomiase humaine africaine à T. gambiense. Med. Trop. 26:1966;357-362.
70. Ollivier G., Legros D. Trypanosomiase humaine africaine: historique de la thérapeutique et de ses échecs. Trop. Med. Int. Health. 6:2001;855-863.
71. WHO (1976) The African Trypanosomiases: Report of a joint WHO Expert Committee and FAO Expert Consultation. WHO Technical Report Series 635.